Sanofi Out Licenses Two Sickle Cell Disease Programs to GBT for $353M

 Sanofi Out Licenses Two Sickle Cell Disease Programs to GBT for $353M

Sanofi Out Licenses Two Sickle Cell Disease Programs to GBT for $353M

Shots:

  • Sanofi to receive ~$353M including $2.25M up front and remaining as development, regulatory and commercial milestones as well as royalties on WW net sales of programs
  • GBT gets exclusive WW rights to two early-stage research programs in SCD. One program pursues a novel anti-sickling mechanism and the other leverages a new approach to reduce inflammation and oxidative stress
  • GBT will conduct all research, development, regulatory and commercialization activities globally. The addition of novel programs will complement GBT’s existing pipeline and support the company’s strategy to address SCD

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Crunch Base

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post